Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
J Clin Psychiatry ; 71(4): 400-10, 2010 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-19925748

RESUMO

OBJECTIVE: This study provides national data on medication access and continuity problems experienced during the first year of the Medicare Part D prescription drug program, which was implemented on January 1, 2006, among a national sample of Medicare and Medicaid "dual eligible" psychiatric patients. METHOD: Practice-based research methods were used to collect clinician-reported data across the full range of public and private psychiatric treatment settings. A random sample of psychiatrists was selected from the American Medical Association Physician Masterfile. Among these physicians, 1,490 provided clinically detailed data on a systematically selected sample of 2,941 dual eligible psychiatric patients. RESULTS: Overall, 43.3% of patients were reported to be unable to obtain clinically indicated medication refills or new prescriptions in 2006 because they were not covered or approved; 28.9% discontinued or temporarily stopped their medication(s) as a result of prescription drug coverage or management issues; and 27.7% were reported to be previously stable on their medications but were required to switch medications. Adjusting for case mix to control for sociodemographic and clinical confounders, the predicted probability of an adverse event among patients with medication access problems was 0.64 compared to 0.36 for those without access problems (P < .0001). All prescription drug utilization management features studied were associated with increased medication access problems (P < .0001). Adjusting for patient case mix, patients with "step therapy" (P < .0001), limits on medication number/dosing (P < .0001), or prior authorization (P < .0001) had 2.4 to 3.4 times the increased likelihood of an adverse event. CONCLUSIONS: More effective Part D policies and management practices are needed to promote clinically safer and appropriate pharmacotherapy for psychiatric patients to enhance treatment outcomes.


Assuntos
Continuidade da Assistência ao Paciente/normas , Acessibilidade aos Serviços de Saúde/normas , Medicaid/normas , Medicare Part D/normas , Transtornos Mentais/tratamento farmacológico , Medicamentos sob Prescrição/uso terapêutico , Psicotrópicos/uso terapêutico , Adulto , Idoso , Grupos Diagnósticos Relacionados/normas , Custos de Medicamentos/estatística & dados numéricos , Feminino , Humanos , Cobertura do Seguro/normas , Seguro de Serviços Farmacêuticos/normas , Masculino , Medicaid/economia , Medicare/economia , Medicare/legislação & jurisprudência , Medicare/normas , Medicare Part D/economia , Conduta do Tratamento Medicamentoso/normas , Transtornos Mentais/psicologia , Pessoa de Meia-Idade , Padrões de Prática Médica/normas , Padrões de Prática Médica/estatística & dados numéricos , Medicamentos sob Prescrição/economia , Medicamentos sob Prescrição/normas , Psiquiatria/normas , Psiquiatria/estatística & dados numéricos , Psicotrópicos/economia , Inquéritos e Questionários , Estados Unidos
2.
Am J Psychiatry ; 164(5): 789-96, 2007 May.
Artigo em Inglês | MEDLINE | ID: mdl-17475738

RESUMO

OBJECTIVE: This study attempted to systematically assess the experiences of Medicare and Medicaid "dual-eligible" psychiatric patients, including evaluating patients' access to medications and the administrative functioning of the program, during the first 4 months of the Medicare Part D prescription drug benefit. METHOD: Psychiatrists (N=5,833) were randomly selected from the American Medical Association's Physicians Masterfile. After exclusion of those not practicing and with undeliverable addresses, 64% responded; 35% met study eligibility criteria of treating at least one dual-eligible patient during their last typical workweek and reported clinically detailed information on one systematically selected patient. RESULTS: A total of 53.4% had at least one medication access problem to report between Jan. 1 and April 30, 2006. Although 9.7% experienced improved medication access, 22.3% discontinued or temporarily stopped taking medication because of prescription drug coverage or management issues, and 18.3% were previously stable but were required to switch medications. Among those with medication access problems, 27.3% experienced a significant adverse clinical event; 19.8% had an emergency room visit. Most drug plan features studied, including preferred drug/formulary lists, prior authorization, medication dosing/number limits, "fail-first" protocols, and requirements to switch to generics, were associated with significantly higher rates of medication access problems. CONCLUSIONS: The findings indicate consequential medication access problems for psychiatric patients during the implementation of Medicare Part D. Although Centers for Medicare and Medicaid Services policies were enacted to ensure access to protected classes of psychopharmacologic medications, the high rates of medication access problems observed indicate further refinement of these policies is needed.


Assuntos
Continuidade da Assistência ao Paciente/normas , Acessibilidade aos Serviços de Saúde , Benefícios do Seguro/normas , Seguro de Serviços Farmacêuticos/normas , Medicaid/legislação & jurisprudência , Medicare/legislação & jurisprudência , Transtornos Mentais/tratamento farmacológico , Adulto , Idoso , Atenção à Saúde/organização & administração , Atenção à Saúde/normas , Custos de Medicamentos , Prescrições de Medicamentos/estatística & dados numéricos , Feminino , Pesquisas sobre Atenção à Saúde , Política de Saúde/legislação & jurisprudência , Humanos , Benefícios do Seguro/legislação & jurisprudência , Seguro de Serviços Farmacêuticos/legislação & jurisprudência , Masculino , Medicaid/normas , Medicare/normas , Pessoa de Meia-Idade , Polimedicação , Psicotrópicos/economia , Psicotrópicos/uso terapêutico , Estados Unidos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA